Core Insights - Hoth Therapeutics, Inc. has announced promising findings for its novel therapeutic candidate HT-001, a topical neurokinin 1 receptor (NK1R) antagonist, aimed at treating Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs) [3][6] Group 1: Clinical Findings - A recent case study highlighted the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer, who experienced full symptom and lesion resolution after one week of treatment, with no recurrence in the following three weeks [2][5] - The patient developed pruritic, burning red papules, a known side effect of EGFR inhibitors, which were effectively treated with HT-001 [2][5] Group 2: Upcoming Presentation - Data regarding HT-001 will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, scheduled for March 7-11, 2025, emphasizing its potential as a breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities [1][4] Group 3: Company Strategy and Research - Hoth Therapeutics is conducting a Phase 2A clinical trial to evaluate the efficacy and safety of HT-001 in a broader patient population, assessing its effectiveness across varying severities of EGFRi PPEs and other dermatologic manifestations induced by EGFR inhibitors [7] - The company aims to address the significant unmet need for long-term, well-tolerated treatment options for cancer patients experiencing debilitating skin reactions [6]

Core Insights - Hoth Therapeutics has announced preclinical findings indicating that Glial Cell Line-Derived Neurotrophic Factor (GDNF) may serve as a groundbreaking treatment for obesity, demonstrating significant reductions in fat accumulation and improvements in metabolism and insulin sensitivity [2][4][6] Group 1: Study Findings - GDNF significantly reduces fat accumulation and enhances metabolism in GDNF-transgenic models, even under high-fat diet conditions [2][4] - The study shows that GDNF increases basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake [6][7] - GDNF inhibits fat cell formation by suppressing key genes involved in fat storage and promoting fat oxidation pathways [6][7] - Enhanced glucose tolerance and lower serum leptin levels in GDNF-tg mice indicate improved metabolic health [6][7] - GDNF prevents hepatic steatosis, a common obesity-related complication, thereby reducing the risk of fatty liver disease [6][7] Group 2: Implications for Obesity Treatment - The findings suggest a paradigm shift in obesity treatment, moving away from traditional methods focused on appetite suppression to a mechanism that enhances the body's natural ability to burn fat [3][4] - GDNF-based therapies could provide a new approach to obesity management by activating natural metabolic processes, representing a significant advancement over current anti-obesity drugs [5][6] Group 3: Future Development Plans - Hoth Therapeutics is exploring various pathways for clinical translation of GDNF-based therapies, including recombinant protein delivery, gene therapy, and small-molecule mimetics [8] - The company plans to initiate further preclinical and clinical development efforts to bring this potential therapy closer to patients [8]

Core Insights - Hoth Therapeutics, Inc. has announced a collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT, marking a significant step in its preclinical development [1][3] - The study focuses on the development and optimization of staining methods for c-Kit markers, which are critical to the therapeutic mechanism of HT-KIT [2] - HT-KIT is a preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers, representing a potential advancement in precision oncology therapies [3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative and impactful treatments aimed at improving patient quality of life [4] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [4]

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The Company received written notification from Nasdaq on January 23, 2025, stating that because the Company's com ...

IP will be used to pursue further indications for HT-001 Cancer TherapeuticNEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline.These newly secured patents reflect Hoth's commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on ...

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the Sequire Investor Summit. To learn more about the Sequire Investor Summit, please visit https://puertorico.srax.com/. About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient ...

Financial Position - The company has no plans for a public or private offering at this time [1][3] - The company maintains a strong financial position with over $10 million in cash and no debt [1][3] - This fiscal strength allows the company to execute strategic initiatives and advance its pipeline without immediate need for additional financing [3] Clinical Trials - Enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants [2][4] - HT-001 is the company's lead therapeutic candidate designed to treat rash and skin disorders associated with cancer therapy [4] - Activating all trial sites for HT-001 marks a significant milestone in the development of this promising therapy [5] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative, patient-focused treatments [2][6] - The company is dedicated to improving patient quality of life through groundbreaking treatments [6] - Hoth collaborates with scientists, clinicians, and key opinion leaders to investigate therapeutics with potential for breakthroughs and diversified treatment options [6] Leadership Statement - The CEO emphasized the company's focus on creating long-term value and advancing clinical programs [4] - The company remains committed to addressing unmet needs for patients undergoing cancer treatment [5] - Hoth is dedicated to transparency and will provide updates as material developments occur [5]

Shares of Hoth Therapeutics (HOTH) skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being developed to address skin toxicities linked to cancer patients undergoing treatment with EGFR inhibitors.Per the data readout from the ongoing phase IIa study, all patients treated with the candidate achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvemen ...

On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors in cancer patients.Data from the open-label portion of the CLEER-001 trial demonstrated:100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.66% of patients reported reduced pain and itching scores, fur ...

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights ...